Multivisceral resection of pancreatic neuroendocrine tumours: a report of two cases

World Journal of Surgical Oncology

Jaswinder S Samra¹  Thomas J Hugh¹  Anthony Gill²  Sivakumar Gananadha¹  Nicholas Williams¹  Raul Alvarado-Bachmann¹  Justin S Gundara¹ 

[1] Department of Gastrointestinal Surgery, Royal North Shore Hospital, University of Sydney, St Leonards NSW 2065, Australia;Department of Anatomical Pathology, Royal North Shore Hospital, University of Sydney, St Leonards NSW 2065, Australia

关键词: GEP-NET;    islet cell carcinoma;    pNET;    neuroendocrine;    pancreatoduodenectomy;   

Others  :  1206672
DOI  :  10.1186/1477-7819-9-93

 received in 2011-05-09, accepted in 2011-08-22,  发布年份 2011

【 摘 要 】

Pancreatic neuroendocrine tumours (pNETs) are rare and surgical resection offers the only possibility of cure for localised disease. The role of surgery in the setting of locally advanced and metastatic disease is more controversial. Emerging data suggests that synchronous surgical resection of pancreas and liver may be associated with increased survival. We report two cases of synchronous, one stage multivisceral resections for pNET and associated reconstruction. We highlight the technical issues involved in such extensive resections and demonstrate that one stage multivisceral operations can be achieved safely.

【 授权许可】

   
2011 Gundara et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Halfdanarson TR, Rabe KG, Rubin J, et al.: Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008, 19:1727-33.
• [2]Bilimoria KY, Tomlinson JS, Merkow RP, et al.: Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastro Surg 2007, 11:1460-67. discussion: 1467-69
• [3]Franko J, Feng W, Yip L, et al.: Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastro Surg 2010, 14:541-48.
• [4]Rindi G, Kloppel G, Alhman H, et al.: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. European Neuroendocrine Tumor Society (ENETS). Virchows Arch 2006, 449:395-401.
• [5]Hellman P, Andersson M, Rastad J, et al.: Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 2000, 24:1353-60.
• [6]Norton J, Kivlen M, Li M, Schneider D, et al.: Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch of Surg 2003, 138:859-66.
• [7]Falconi M, Plockinger U, Kwekkeboom D, et al.: Well-differentiated pancreatic non-functioning tumours/carcinoma. Neuroendo 2006, 84:196-211.
• [8]Sarmiento JM, Heywood G, Rubin J, et al.: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003, 197:29-37.
• [9]Cattell RB, Braasch JW: A technique for the exposure of the third and fourth portions of the duodenum. Surg Gynecol Obstet 1960, 111:378-79.
• [10]Thompson G, van Heerden J, Grant C, et al.: Islet cell carcinomas of the pancreas: a twenty-year experience. Surg 1988, 104:1011-7.
• [11]Solorzano C, Lee J, Pisters P, et al.: Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surg 2001, 130:1078-85.
• [12]Chen H, Hardacre J, Uzar A, et al.: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998, 187:88-92.
• [13]Bettini R, Mantovani W, Boninsegna L, et al.: Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liv Dis 2009, 41:49-55.
• [14]Le Treut YP, Gregoire E, Belghiti J, et al.: Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transpl 2008, 8:1205-13.
• [15]Rinke A, Muller H, Schade-Brittinger C, et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Onc 2009, 27:4656-63.
• [16]Raymond E, Dahan L, Raoul J, et al.: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Eng J Med 2011, 364:501-13.
• [17]Klimstra D, Modlin I, Adsay N, et al.: Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Path 2010, 34:300-13.
• [18]Yang Z, Tang L, Klimstra D: Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Path 2011, 35:853-60.